Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
ProQR Therapeutics 2019
Volgen
looks like the Usher interim results will be pushed to Q1 2020 .. thats why i see some weakness.. but maybe the CEO will explain or come p with something positive in the presentation today. bummer
joel12 schreef op 19 juni 2019 17:36 :
looks like the Usher interim results will be pushed to Q1 2020 .. thats why i see some weakness.. but maybe the CEO will explain or come p with something positive in the presentation today. bummer
What is your source? Has this been communicated? The JMP securities Life Sciences meeting will be held on june 19th (after closure of the stock market?) +20th. Keep us informed pleased.
Tom3 schreef op 18 juni 2019 23:51 :
[...]
Tja, nu koop je bijna 2,5 ProQR aandelen als je 1 Arrowhead inlevert. Zijn er hier die dat gedaan hebben?
Ik ben toch nieuwsgierig waarom jij dit vraagt? Zie je meer potentie in ProQR dan in Arrowhead? Arrowhead draait de laatste tijd toch beter dan ProQR. Of zit volgens jou Arrowhead nu op het hoogtepunt en ProQR op het dieptepunt? Heb jij gewisseld?
the presentation is on right now. i simply see the difference of what was communicated previously vs the new presentation. but now the CEO presents why.. they thought the data will be too thin to had been presented now. the next data will be the full phase1/2 Sapufrosen in Fall
very powerful presentation from the CEO .. and lots of info including competitive against DNA editing.
joel12 schreef op 19 juni 2019 18:55 :
very powerful presentation from the CEO .. and lots of info including competitive against DNA editing.
Yes I have just heard the final 10 minutes of the presentation. I think the delay was avoidable because the knew what they were doing upfront, so this is a second mistake of Mr de Boer (after the DEB failure). A very costly mistake for De Boer as he is a major shareholder too. We will see what will happen.
betekent niet dat de potentie er minder om is, maar zijn lange processen. Wat wel vervelend is, is dat de boven de effectenmarkten altijd aasgieren circuleren die voordeel willen behalen bij twijfel en onzekerheid. Ik vind het wel jammer dat het er naar uitziet dat het nog een poosje dood geld lijkt te worden....geen actie. Ik heb toch wel een trauma overgehouden aan UniQure...zat erin op 3,80$...ging ff richting 40$....toen tot onder de 5$ (ik was ondertussen rond 13,50$ uitgestapt omdat feeling weg was)...dobbelde een beetje rond de kaspositie van toen 5$....en nu inmiddels 81$ gezien (anderhalf jaar later!)...het kan verkeren!
@ ivet, ja het is vandaag weer een dure dag.. De Boer had dit toch van te voren kunnen bedenken. De beursreactie vandaag valt me ergens nog mee ook. Het is een geluk dat 85% van de aandelen bij grote instituten zitten. Wellicht hadden die dit al zien aankomen na de DEB zeperd. Een derde miskleun zou dodelijk kunnen zijn. Kennelijk heeft men sedert dit voorjaar weinig verbetering gezien. Allemaal niet sterk dus.
the DEB never failed .. the product simply doesnt make sense strategically for proqr. as to the delay .. someone can say it is a sign of confindence that they are kept blinded for a longer period. they simply know they have a good drug. as to the CEO .. and us shareholders ... PROQR has so many avenues to cut a money , valuable business partnership.. it waits and thats the Dutch way no>? :) patience.
joel12 schreef op 19 juni 2019 20:47 :
the DEB never failed .. the product simply doesnt make sense strategically for proqr.
as to the delay .. someone can say it is a sign of confindence that they are kept blinded for a longer period. they simply know they have a good drug.
as to the CEO .. and us shareholders ... PROQR has so many avenues to cut a money , valuable business partnership.. it waits and thats the Dutch way no>? :) patience.
Hi joel12, If DEB hadn`t been ousted the SP would still have been around $ 16 or higher. It is not clear to me why they haven`t made any hints towards the efficacy of the Usher drug. Have you heard any hint?
joel12 schreef op 19 juni 2019 20:47 :
the DEB never failed .. the product simply doesnt make sense strategically for proqr.
as to the delay .. someone can say it is a sign of confindence that they are kept blinded for a longer period. they simply know they have a good drug.
as to the CEO .. and us shareholders ... PROQR has so many avenues to cut a money , valuable business partnership.. it waits and thats the Dutch way no>? :) patience.
agree...other risk perception; the effect on the eye is more predictable but a whole treated body (DEB) is something else! There is no CEO that can satisfy all shareholders at once!
the company for 1 reason or another keeps the price low for now. the main issue it had was not the DB which is still ongoing and the market for it its not big and does have also a big threat from CRISPr , gene therapy. the main issue was the safety of the opthamological drug creating cataracts. AND this was given very strong explanation as to why and also competitively in the latest JMP presentation. I feel ever more comfindent about the safety and future of the ophtamological franchise. many or most small mid cap biotech stocks have gone down in the past mohths, many without any bad news of any kind. as we move towards XBI 90 and beyond they will recover and I hope PRQR as well. the low share price for an intermediate period hope was used by the company to hire good employees and for its big shareholders to consolidate the positions. Lastly in fall they are faced with a big event! the phase1/2 data.. which runs parallel to phase3. very important for the data to be good. i wonder if they will manage risk by partnering before this event to get money, or raise further capital.
right! and we cant see what he sees.. only in due time :)
joel12 schreef op 20 juni 2019 02:44 :
the company for 1 reason or another keeps the price low for now. the main issue it had was not the DB which is still ongoing and the market for it its not big and does have also a big threat from CRISPr , gene therapy.
the main issue was the safety of the opthamological drug creating cataracts. AND this was given very strong explanation as to why and also competitively in the latest JMP presentation. I feel ever more comfindent about the safety and future of the ophtamological franchise.
many or most small mid cap biotech stocks have gone down in the past mohths, many without any bad news of any kind. as we move towards XBI 90 and beyond they will recover and I hope PRQR as well. the low share price for an intermediate period hope was used by the company to hire good employees and for its big shareholders to consolidate the positions.
Lastly in fall they are faced with a big event! the phase1/2 data.. which runs parallel to phase3. very important for the data to be good. i wonder if they will manage risk by partnering before this event to get money, or raise further capital.
Thanks for your observations. My issue is that the market now has to believe De Boer regarding the delay: is it a delay only or is it the first step in a complete failure of the Usher trial? I also can`t believe that all the pre- clinical research done and the lca10 trial experience won`t pay off. Still it is very important to manage expectations in a timely fashion. Here De Boer made a glitch. Somehow the market has reacted already as there was no big sell-off yesterday. Volumes were modest. I hope this will continue. Therefore I appreciate your remarks regarding the strong JMP presentation of De Boer, we will need that. Tn my opinion strong Usher data have to trigger a fresh capital increase, as De Boer has plenty of money well into 2021. Investors don`t like to pay for the lca10 data twice.
Kan het ook in het Nederlands jongens,want niet iedereen kan hier volgen,het is tenslotte een Nederlands forum. En Proqr gaat weer down,down,down,je kan er blind elings op vertrouwen,terwijl mijn gala aandeeltjes up,up up gaan.Wat een verschil toch.
Ik heb gister mijn positie in proqr gesloten. Dank voor je melding joel. Hoe kun je nu een maand voor het nieuws de boel 3 kwart jaar opschuiven. Das niet omdat de resultaten sprekend waren. Ik denk uitstel in de hoop dat langer behandelen betere resultaten levert. Iemand een andere mening? Het is hoe dan ook dodelijk voor het vertrouwen zo'n actie.
nmgn schreef op 20 juni 2019 19:40 :
Ik heb gister mijn positie in proqr gesloten. Dank voor je melding joel. Hoe kun je nu een maand voor het nieuws de boel 3 kwart jaar opschuiven. Das niet omdat de resultaten sprekend waren. Ik denk uitstel in de hoop dat langer behandelen betere resultaten levert. Iemand een andere mening?
Het is hoe dan ook dodelijk voor het vertrouwen zo'n actie.
Ja het vertrouwen in De Boer is even helemaal zoek, de volumes zijn nog klein maar het is duidelijk dat de stukken die aangeboden worden met de nek worden aangekeken. Als je zo`n trial opstart dan weet je toch dat wat je aan het doen bent en dat je niet al na 3 maanden sprekende resultaten hebt. Wat de nieuwe bodem is? Vorig jaar brak men de tent af en werd er $ 15 per aandeel geboden bij de laatste emissie. Als er nu een stilzwijgende afspraak is dat niemand zijn nek gaat uitsteken zijn we zo weer bij de $ 7.
Idd heel jammer. Wat er heel snel is bijgekomen is evensnel verdwenen.
ik heb ook mijn proqr er uit gelazerd ,heb er geen vertrouwen meer in deze toko hoop dat vele dat ook gaan doen,ben maar een kleine belegger 225 stuks
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee